Castleview Partners, LLC Cardiff Oncology, Inc. Transaction History
Castleview Partners, LLC
- $111 Million
- Q1 2025
A detailed history of Castleview Partners, LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Castleview Partners, LLC holds 14,465 shares of CRDF stock, worth $40,791. This represents 0.04% of its overall portfolio holdings.
Number of Shares
14,465Holding current value
$40,791% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding CRDF
# of Institutions
130Shares Held
25.4MCall Options Held
866KPut Options Held
203K-
Commodore Capital LP New York, NY5.38MShares$15.2 Million2.34% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$7.41 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$6.44 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.54MShares$4.34 Million0.18% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.44MShares$4.07 Million3.38% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $122M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...